Adaptimmune Therapeutics Plc, a commercial-stage cell therapy company based in Abingdon, Oxfordshire, focuses on novel T-cell therapies for cancer, including afamitresgene autoleucel and Lete-cel. The company employs 449 people and went public on May 6, 2015.
Adrian Rawcliffe sold 30,473 shares of ADAP on 13 January at $0.59 per share, worth a total of $18K. They now own 25,711 ADAP shares, or a 63% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
